0000000001246346

AUTHOR

G. Tedeschi

showing 16 related works from this author

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

2014

Objective: The objective of this paper is to identify clinical or magnetic resonance imaging (MRI) predictors of long-term clinical progression in a large cohort of multiple sclerosis (MS) patients. Methods: A total of 241 relapsing–remitting (RR) MS patients were included in a nine-year follow-up (FU) study. The reference MRIs were acquired at baseline (BL) as part of a multicenter, cross-sectional, clinical-MRI study. Volumetric MRI metrics were measured by a fully automated, operator-independent, multi-parametric segmentation method. Clinical progression was evaluated as defined by: conversion from RR to secondary progressive (SP) disease course; progression of Expanded Disability Status…

AdultMalemedicine.medical_specialtyMagnetic resonance imaging follow-up multiple sclerosis clinical predictors gray matter atrophypredictormultiple sclerosisDisease courseDisability EvaluationMultiple Sclerosis Relapsing-RemittingInternal medicinefollow-upmedicineHumansSecondary progressiveExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosisDisease progressionFollow up studiesMagnetic resonance imagingclinical predictorsMiddle Agedmedicine.diseaseMagnetic Resonance Imaginggray matter atrophyCross-Sectional StudiesNeurologymultiple sclerosiDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessNuclear medicineClinical progressionMRIFollow-Up StudiesMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

2015

Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS). Methods: As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were e…

AdultMale0301 basic medicineamyotrophic lateral sclerosismedicine.medical_specialtyALS - TUDCA - clinical trialmedicine.drug_classPilot ProjectsAmyotrophic lateral sclerosis; Cholic acids; Tauroursodeoxycholic acid; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Drug Therapy Combination; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Riluzole; Taurochenodeoxycholic Acid; Outcome Assessment (Health Care); Neurology; Neurology (clinical)PlaceboNeuroprotectionGastroenterologyTaurochenodeoxycholic AcidOutcome Assessment (Health Care)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodDrug TherapyInternal medicinemedicineCholic acidHumansAmyotrophic lateral sclerosisAdverse effectAmyotrophic lateral sclerosiAgedtauroursodeoxycholic acidRiluzoleBile acidbusiness.industryTauroursodeoxycholic acidMiddle Agedmedicine.diseaseRiluzoleSurgerySettore MED/26 - NEUROLOGIANeuroprotective Agentscholic acids030104 developmental biologyNeurologychemistryTolerabilityCombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugEuropean Journal of Neurology
researchProduct

Being the Family Caregiver of a Patient With Dementia During the Coronavirus Disease 2019 Lockdown

2021

Background: Family caregivers of patients with dementia are at high risk of stress and burden, and quarantine due to the coronavirus disease 2019 (COVID-19) pandemic may have increased the risk of psychological disturbances in this population. The current study was carried out during the national lockdown declared in March 2020 by the Italian government as a containment measure of the first wave of the coronavirus pandemic and is the first nationwide survey on the impact of COVID-19 lockdown on the mental health of dementia informal caregivers.Methods: Eighty-seven dementia centers evenly distributed on the Italian territory enrolled 4,710 caregiver–patient pairs. Caregivers underwent a tel…

Agingmedicine.medical_specialtyCognitive NeurosciencePopulationPsychological interventionProtective factorNeurosciences. Biological psychiatry. Neuropsychiatryburden03 medical and health sciencesstress0302 clinical medicinestremedicineDementiaburden; caregiver; COVID-19; dementia; stressPsychiatryeducationcaregiverOriginal ResearchMED/26 - NEUROLOGIAeducation.field_of_study030214 geriatricsburden caregiver COVID-19 dementia stressFamily caregiversbusiness.industryCOVID-19COVID-19; burden; caregiver; dementia; stressmedicine.diseaseMental healthSettore MED/26 - NEUROLOGIAAnxietyCaregiver stressM-PSI/08 - PSICOLOGIA CLINICAmedicine.symptombusiness030217 neurology & neurosurgeryNeuroscienceRC321-571dementia
researchProduct

Towards the standardization of mitochondrial proteomics: the Italian mt-HPP initiative

2017

The mitochondrial Human Proteome Project aims at understanding the function of the mitochondrial proteome and its crosstalk with the proteome of other organelles. Being able to choose a suitable and validated enrichment protocol of functional mitochondria, based on the specific needs of the downstream proteomics analysis, would greatly help the researchers in the field. Mitochondrial fractions from ten model cell lines were prepared using three enrichment protocols and analyzed on seven different LC-MS/MS platforms. All data were processed using neXtProt as reference database. The data are available for the Human Proteome Project purposes through the ProteomeXchange Consortium with the iden…

itlian mt-HPP iniziativeMitochondria standardization enrichment protocol Mitochondrial Human Proteome Projectmitochondrial proteomicBIO/10 - BIOCHIMICAproteomic
researchProduct

Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study.

2005

Knowledge about the balance between heritable and nonheritable risk in multiple sclerosis (MS) is based on twin studies in high-prevalence areas. In a study that avoided ascertainment limitations and directly compared continental Italy (medium-prevalence) and Sardinia (high-prevalence), we ascertained 216 pairs from 34,549 patients. This gives a twinning rate of 0.62% among MS patients, significantly less than that of the general population. In continental Italy, probandwise concordance was 14.5% (95% confidence interval, 5.1-23.8) for monozygotic and 4.0% (95% confidence interval, 0.8-7.1) for dizygotic twins. Results in Sardinia resemble those in northern populations but in limited number…

MaleQuestionnairesMultiple SclerosisConcordancePopulationTwinsDizygotic twinsDisease causeMultiple Sclerosis Epidemiology TwinsCohort StudiesCohort Studies Disease Susceptibility Female Genetic Predisposition to Disease Humans Italy; epidemiology Male Multiple Sclerosis; epidemiology/genetics Questionnaires Regression Analysis TwinsSurveys and QuestionnairesmedicineHumansGenetic Predisposition to Diseaseeducationeducation.field_of_studyepidemiology/geneticsbusiness.industryMultiple sclerosismedicine.diseasePenetranceTwin studyConfidence intervalNeurologyItalyRegression AnalysisSettore MED/26 - NeurologiaFemaleepidemiologyNeurology (clinical)Disease SusceptibilitybusinessDemography
researchProduct

Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis

2006

Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However, in the literature there are inconsistent reports on the prevalence of cognitive dysfunction, and separate data for the relapsing-remitting (RR) type of the disease are not always presented. In this study, we submitted 461 RRMS patients to a battery of neuropsychological tests to investigate their impairment in various cognitive domains. As a consequence of the exclusion criteria, the sample is not fully representative of the entire population of RRMS patients. In this selected sample, when only the eight scores of a core battery (Mental Deterioration Battery) were considered (with respectiv…

Adult050103 clinical psychologymedicine.medical_specialtyMultiple Sclerosismultiple sclerosis cognition single digit modality test information processingNeuropsychological TestsAudiologyDevelopmental psychology03 medical and health sciencesCognitionMultiple Sclerosis Relapsing-Remitting0302 clinical medicineMemoryOutpatientsOutpatients; Humans; Patient Selection; Multiple Sclerosis Relapsing-Remitting; Cognition; Cognition Disorders; Italy; Demography; Memory; Adult; Language; Neuropsychological Tests; SpeechmedicineHumansSpeech0501 psychology and cognitive sciencesMemory disorderCognitive deficitDemographyLanguagemedicine.diagnostic_testPatient SelectionMemoriaMultiple sclerosiscognition impairment05 social sciencesCognitive disorderNeuropsychologyCognitionNeuropsychological testmedicine.diseaserelapsing-remittingItalyinformation processing speedNeurologymultiple sclerosiSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptomCognition DisordersPsychology030217 neurology & neurosurgeryrelapsing remitting
researchProduct

Reply to Dr Michaudet al.

2015

There is no abstract

Cholagogues and Cholereticsbusiness.industryEndoplasmic reticulumAmyotrophic Lateral SclerosisTaurochenodeoxycholic acidTauroursodeoxycholic acidMitochondrionPharmacologyEndoplasmic Reticulummedicine.diseaseTaurochenodeoxycholic Acidchemistry.chemical_compoundNeurologychemistryImmunologyUnfolded Protein ResponsemedicineUnfolded protein responseAnimalsHumansTUDCA ALSSettore MED/26 - NeurologiaNeurology (clinical)Amyotrophic lateral sclerosisbusinessEuropean Journal of Neurology
researchProduct

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

2019

Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TR…

Adultmedicine.medical_specialtyDiscontinuation rateTime FactorsToluidinesPopulationHydroxybutyratesRelapsing-RemittingDimethyl fumarateMultiple sclerosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideNitrilesTeriflunomidemedicineHumansMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDimethyl fumaratebusiness.industryProportional hazards modelMultiple sclerosisDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Neurology; Neurology (clinical)Real-lifeRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationchemistryItalyNeurologyCrotonatesCohortDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Adult; Crotonates; Dimethyl Fumarate; Follow-Up Studies; Humans; Immunosuppressive Agents; Italy; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; Time Factors; ToluidinesNeurology (clinical)business030217 neurology & neurosurgeryImmunosuppressive AgentsFollow-Up Studies
researchProduct

TREATMENT OF MULTIPLE SCLEROSIS WITH INTERFERON BETA IN CLINICAL PRACTICE: 2-YEAR FOLLOW-UP DATA FROM THE SOUTH ITALY MOBILE MRI PROJECT

2006

researchProduct

The impact of classes of innovators on Technology, Financial Fragility and Economic Growth

2011

In this paper, we study innovation processes and technological change in an agent-based model. By including a behavioral switching among heterogeneous innovative firms, which can endogenously change among three different classes (single innovators, collaborative innovators and imitators) on the base of their R&D expenditures, the model is able to replicate, via simulations, well known industrial dynamic and growth type stylized facts. Moreover, we focus the analysis on the impact of these three innovation categories on micro, meso and macro aggregates. We find that collaborative companies are those having the highest positive impact on the economic system. The model is then used to study th…

jel:C63jel:E32Computational economics business cycle innovation policy technologyjel:E6Computational economics business cycle innovation policy technologyjel:O3jel:O4
researchProduct

A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy

2007

Mutations in the Angiogenin gene (ANG) linked to 14q11.2 have been recently discovered to be associated with Amyotrophic Lateral Sclerosis (ALS) in Irish and Scottish populations. In our study we investigated the role of ANG gene in ALS patients from southern Italy. We found a novel mutation in the signal peptide of the ANG gene in a sporadic patient with ALS (SALS). The molecular analysis of the ANG gene also demonstrated an allelic association with the rs11701 single nucleotide polymorphism (SNP) in familial ALS (FALS) but not in SALS patients. Our finding supports the evidence that the ANG gene is involved in ALS.

AdultGenetic MarkersMaleSignal peptideAngiogenin geneAngiogeninGenetic LinkageDNA Mutational AnalysisSingle-nucleotide polymorphismGene mutationBiologyPolymorphism Single NucleotidemedicineHumansSNPGenetic Predisposition to DiseaseGenetic TestingAlleleAmyotrophic lateral sclerosisGeneGenetics (clinical)AgedChromosomes Human Pair 14Motor NeuronsGeneticsAmyotrophic Lateral SclerosisChromosome MappingRibonuclease PancreaticMiddle Agedmedicine.diseaseAssociation studyAmino Acid SubstitutionItalyNeurologyCytoprotectionMutationNerve DegenerationPediatrics Perinatology and Child Healthcardiovascular systemCancer researchFemaleNeurology (clinical)ALShormones hormone substitutes and hormone antagonistsNeuromuscular Disorders
researchProduct

GREY MATTER ATROPHY AND FATIGUE IN MULTIPLE SCLEROSIS: A CORRELATION EVIDENT ONLY IN PATIENTS WITH LOW DISABILITY

2006

researchProduct

Genetic counselling in ALS: facts, uncertainties and clinical suggestions

2013

The clinical approach to patients with amyotrophic lateral sclerosis (ALS) has been largely modified by the identification of novel genes, the detection of gene mutations in apparently sporadic patients, and the discovery of the strict genetic and clinical relation between ALS and frontotemporal dementia (FTD). As a consequence, clinicians are increasingly facing the dilemma on how to handle genetic counselling and testing both for ALS patients and their relatives. On the basis of existing literature on genetics of ALS and of other late-onset life-threatening disorders, we propose clinical suggestions to enable neurologists to provide optimal clinical and genetic counselling to patients and…

medicine.medical_specialtyGenotypeGENETICSGenetic counselingGenetic CounselingGene mutationSettore MED/03 - GENETICA MEDICAmedicineHumansGenetic TestingAmyotrophic lateral sclerosisGenetic discriminationPsychiatryGenetic testingmedicine.diagnostic_testbusiness.industryAmyotrophic Lateral Sclerosismedicine.diseasePenetranceALS; GENETICS3. Good healthPsychiatry and Mental healthPhenotypeFrontotemporal DementiaMutationSurgerySettore MED/26 - NeurologiaNeurology (clinical)ALSbusinessMotor neurone diseaseFrontotemporal dementiaJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis.

2013

MATR3 is an RNA- and DNA-binding protein that interacts with TDP-43, a disease protein linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Using exome sequencing, we identified mutations in MATR3 in ALS kindreds. We also observed MATR3 pathology in ALS-affected spinal cords with and without MATR3 mutations. Our data provide more evidence supporting the role of aberrant RNA processing in motor neuron degeneration. © 2014 Nature America, Inc. All rights reserved.

MaleAged Aged; 80 and over Amyotrophic Lateral Sclerosis; genetics/pathology Computational Biology DNA Mutational Analysis DNA-Binding Proteins; metabolism Family Health Female Genetic Predisposition to Disease; genetics Genotype Humans Male Middle Aged Muscle; Skeletal; metabolism/pathology Mutation; genetics Neurologic Examination Nuclear Matrix-Associated Proteins; genetics/metabolism RNA-Binding Proteins; genetics/metabolism Spinal Cord; metabolism/pathologyDNA Mutational Analysisgenetics/metabolismRNA-binding proteinSettore MED/03 - GENETICA MEDICAmedicine.disease_cause0302 clinical medicineNuclear Matrix-Associated ProteinsGenotype80 and overgeneticsAmyotrophic lateral sclerosisExome sequencingGeneticsAged 80 and overNeurologic Examination0303 health sciencesMutationGeneral NeuroscienceRNA-Binding ProteinsSkeletalMiddle AgedDNA-Binding ProteinsMATR3medicine.anatomical_structureSpinal Cordfamilial amyotrophic lateral sclerosisMuscleSettore MED/26 - NeurologiaFemaleFrontotemporal dementiametabolism/pathologyGenotypeArticle03 medical and health sciencesgenetics; familial amyotrophic lateral sclerosismental disordersmedicineHumansGenetic Predisposition to DiseaseMuscle Skeletal030304 developmental biologyAgedFamily Healthbusiness.industryAmyotrophic Lateral Sclerosisgenetics/pathologyRNAComputational BiologySpinal cordmedicine.diseaseMutationgeneticbusinessNeurosciencemetabolism030217 neurology & neurosurgery
researchProduct

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

2009

At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients t…

AdultMalemedicine.medical_specialtyPediatricsNeurologyMultiple SclerosisPatient DropoutsDatabases FactualAlternative medicineDermatologyPharmacologyAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingMedicineHumansGlatiramer acetateMultiple sclerosis NatalizumabSurveillance programPharmacovigilancebusiness.industryMultiple sclerosisNatalizumabAntibodies MonoclonalDrug agencyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYSettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerybusinessmedicine.drugFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

An exploration of anger phenomenology in multiple sclerosis

2009

Background and purpose:  Multiple sclerosis (MS) patients are often emotionally disturbed. We investigated anger in these patients in relation to demographic, clinical, and mood characteristics. Patients and methods:  About 195 cognitively unimpaired MS patients (150 relapsing–remitting and 45 progressive) were evaluated with the State Trait Anger Expression Inventory, the Chicago Multiscale Depression Inventory, and the State Trait Anxiety Inventory. The patients’ anger score distribution was compared with that of the normal Italian population. Correlation coefficients among scale scores were calculated and mean anger scores were compared across different groups of patients by analysis of …

business.industryMultiple sclerosismedia_common.quotation_subjectAngermedicine.diseasebehavioral disciplines and activitiesCorrelationMoodNeurologymental disordersbehavior and behavior mechanismsmedicineAnxietyNeurology (clinical)Analysis of variancemedicine.symptomPrefrontal cortexbusinesspsychological phenomena and processesState-Trait Anxiety InventoryClinical psychologymedia_commonEuropean Journal of Neurology
researchProduct